New GASA Report Estimates $688 Billion in Scam Losses Across Asia Amid Rising Cyberthreat Worldwide
2024 Asia Scam Report Reveals Singapore and Japan See Decline in Scam Losses
SINGAPORE / ACCESSWIRE / October 14, 2024 / The Global Anti-Scam Alliance (GASA) has released the highly anticipated 2024 Asia Scam Report. Based on survey responses from 24,731 consumers across Asia, this annual report offers insights into the growing threat posed by scammers and their increasingly sophisticated tactics.
Individual survey responses were extrapolated to report an estimated total loss of $688.42 billion over the last 12 months, a figure that represents a significant portion of the estimated $1.026 trillion global scam losses reported in GASA's 2023 data. This year's report highlights key trends such as the rise of AI-generated scam messages and the surge in social media-related fraud.
Key Findings from the 2024 Asia Scam Report:
Rapid Revictimization: Scam victims across Asia tend to be scammed repeatedly after they have been successfully targeted once.
Singapore (-40%) and Japan (-17%) have reported a noteworthy reduction in average scam loss per victim, indicating the effectiveness of preventive measures while other countries have seen increases. In Singapore, initiatives such as the co-location of police and banks has contributed to an efficient crackdown on scams.
Dominance of Social Media Scams: Some leading platforms have seen an increase in scam activity, with many users looking for social platforms to address fraudulent ads and fake accounts.
Top Scams by Category: Identity theft, investment scams, and shopping scams remain the leading threats across the region, with scammers targeting individuals through a range of channels, including phone calls, social media, and text messages.
Scam Prevention and Cross-Sector Collaboration in Focus at GASS Asia Summit
As Foundation Partners of GASA, Mastercard and ScamAdviser sponsored this report and will engage deeply in scam prevention discussions and partnerships at the Global Anti-Scam Summit (GASS) Asia Summit on October 20-21. The event, in Singapore, is a key gathering for stakeholders across sectors to joint actions against perpetrators of scams. With Amazon, Google, and other global organizations participating, the event will focus on best practices and new strategies in financial fraud, AI misuse, and consumer protection strategies.
For more information and to download the full 2024 Asia Scam Report, visit GASA's official website.
Contact Information
Sam Rogers
Marketing Director, Global Anti-Scam Alliance
sam.rogers@gasa.org
SOURCE: Global Anti-Scam Alliance (GASA)
View the original press release on newswire.com.
Global Anti-Scam Alliance
Subscribe to releases from Accesswire
Subscribe to all the latest releases from Accesswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Accesswire
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press Release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press Release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press Release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press Release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press Release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom